These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

899 related items for PubMed ID: 8774208

  • 1. Effect of isoniazid chemoprophylaxis on HIV-related mycobacterial disease.
    Graham NM, Galai N, Nelson KE, Astemborski J, Bonds M, Rizzo RT, Sheeley L, Vlahov D.
    Arch Intern Med; 1996 Apr 22; 156(8):889-94. PubMed ID: 8774208
    [Abstract] [Full Text] [Related]

  • 2. Influence of the human immunodeficiency virus in the incidence of tuberculosis in a cohort of intravenous drug users: effectiveness of anti-tuberculosis chemoprophylaxis.
    Jansà JM, Serrano J, Caylà JA, Vidal R, Ocaña I, Español T.
    Int J Tuberc Lung Dis; 1998 Feb 22; 2(2):140-6. PubMed ID: 9580481
    [Abstract] [Full Text] [Related]

  • 3. Isoniazid preventive therapy in human immunodeficiency virus-infected persons. Long-term effect on development of tuberculosis and survival.
    Moreno S, Miralles P, Diaz MD, Baraia J, Padilla B, Berenguer J, Alberdi JC.
    Arch Intern Med; 1998 Feb 22; 157(15):1729-34. PubMed ID: 9250234
    [Abstract] [Full Text] [Related]

  • 4. Preventive chemotherapy for HIV-associated tuberculosis in Uganda: an operational assessment at a voluntary counselling and testing centre.
    Aisu T, Raviglione MC, van Praag E, Eriki P, Narain JP, Barugahare L, Tembo G, McFarland D, Engwau FA.
    AIDS; 1995 Mar 22; 9(3):267-73. PubMed ID: 7755915
    [Abstract] [Full Text] [Related]

  • 5. Reduction of clinical tuberculosis in HIV-infected males with isoniazid prophylaxis.
    Alaei K, Alaei A, Mansouri D.
    East Mediterr Health J; 2002 Nov 22; 8(6):754-7. PubMed ID: 15568452
    [Abstract] [Full Text] [Related]

  • 6. High risk of active tuberculosis in HIV-infected drug users with cutaneous anergy.
    Selwyn PA, Sckell BM, Alcabes P, Friedland GH, Klein RS, Schoenbaum EE.
    JAMA; 2002 Nov 22; 268(4):504-9. PubMed ID: 1619742
    [Abstract] [Full Text] [Related]

  • 7. Tuberculosis chemotherapy and sputum conversion among HIV-seropositive and HIV-seronegative patients in south-eastern Uganda.
    Bwire R, Borgdorff MW, Sticht-Groh V, Rieder HL, Kawuma HJ, Bretzel G, Rüsch-Gerdes S.
    East Afr Med J; 1999 Jun 22; 76(6):307-13. PubMed ID: 10750516
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Prophylaxis of mycobacterial infections in immunocompromised patients.
    Krance MB, Fisher MA.
    Am Fam Physician; 1996 Nov 01; 54(6):1981-8, 1991-2. PubMed ID: 8900358
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Effect of isoniazid prophylaxis on incidence of active tuberculosis among Thai HIV-infected individuals.
    Saenghirunvattana S.
    J Med Assoc Thai; 1996 May 01; 79(5):285-7. PubMed ID: 8708519
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. [Tuberculosis in compromised hosts].
    Kekkaku; 2003 Nov 01; 78(11):717-22. PubMed ID: 14672050
    [Abstract] [Full Text] [Related]

  • 14. [HIV infection, tuberculosis and tuberculin test in Switzerland. The Swiss HIV Cohort Study].
    Sudre P, Rieder H, Bassetti S, Hirschel BJ, Ledergerber B, Malvy D.
    Schweiz Med Wochenschr; 1996 Nov 23; 126(47):2007-12. PubMed ID: 8984608
    [Abstract] [Full Text] [Related]

  • 15. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection.
    Selwyn PA, Hartel D, Lewis VA, Schoenbaum EE, Vermund SH, Klein RS, Walker AT, Friedland GH.
    N Engl J Med; 1989 Mar 02; 320(9):545-50. PubMed ID: 2915665
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. A controlled trial of isoniazid in persons with anergy and human immunodeficiency virus infection who are at high risk for tuberculosis. Terry Beirn Community Programs for Clinical Research on AIDS.
    Gordin FM, Matts JP, Miller C, Brown LS, Hafner R, John SL, Klein M, Vaughn A, Besch CL, Perez G, Szabo S, El-Sadr W.
    N Engl J Med; 1997 Jul 31; 337(5):315-20. PubMed ID: 9233868
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Association of tuberculosis risk with the degree of tuberculin reaction in HIV-infected patients. The Gruppo Italiano di Studio Tubercolosi e AIDS.
    Girardi E, Antonucci G, Ippolito G, Raviglione MC, Rapiti E, Di Perri G, Babudieri S.
    Arch Intern Med; 1997 Apr 14; 157(7):797-800. PubMed ID: 9125013
    [Abstract] [Full Text] [Related]

  • 20. The changing pattern of AIDS-defining illnesses with the introduction of highly active antiretroviral therapy (HAART)in a London clinic.
    Ives NJ, Gazzard BG, Easterbrook PJ.
    J Infect; 2001 Feb 14; 42(2):134-9. PubMed ID: 11531320
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 45.